You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科倫博泰生物-B(06990.HK)治療乳腺癌藥物研究疾病控制率89.5%
阿思達克 10-16 08:49
科倫博泰生物-B(06990.HK)公佈,將在於10月20至24日在西班牙馬德里舉行的2023年歐洲腫瘤內科學會(ESMO)大會上,以口頭報告的形式公佈創新TROP2-ADC(SKB264,亦稱爲MK-2870)用於治療激素受體陽性(HR+)和人表皮生長因子受體2陰性(HER2-)轉移性乳腺癌(mBC)患者的1/2期籃子研究的研究結果。 公司指出,在38名可評估療效的患者中,47%的患者出現原發內分泌耐藥性。客觀緩解率(ORR)爲36.8%,疾病控制率(DCR)爲89.5%。中位持續緩解時間(DoR)爲7.4個月,6個月DoR率爲80%。中位無進展生存期(PFS)爲11.1個月,6個月PFS率爲61.2%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account